Table 11.6d

Immunosuppression Use for Maintenance by Regimen

Prior to Discharge, 1997 to 2006

Recipients with Heart Transplants

  Transplant Year
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Functioning Graft at Discharge 2,068 2,119 1,922 1,982 2,008 1,972 1,897 1,867 1,957 2,040
With Immunosuppression Info 2,048 2,109 1,912 1,976 1,983 1,961 1,883 1,846 1,935 1,982
--- + MMF/MPA 0.0% 0.2% 0.1% 0.1% 0.0% 0.0% 0.1% 0.1% 0.1% 0.2%
--- + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0%
--- + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.1% 0.1%
--- + MMF/MPA + Steroids 0.8% 0.9% 0.8% 1.1% 0.4% 0.8% 0.4% 0.8% 1.1% 0.9%
--- + OtherAntimet 0.0% 0.0% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0%
--- + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0%
--- + OtherAntimet + Steroids 1.7% 0.7% 0.6% 0.2% 0.1% 0.1% 0.0% 0.5% 0.8% 0.1%
--- + Siro/Evero + Steroids 0.0% 0.0% 0.0% 0.2% 0.2% 0.2% 0.1% 0.1% 0.1% 0.1%
--- + Steroids 0.7% 1.4% 1.6% 2.5% 0.8% 1.9% 1.1% 0.6% 0.4% 0.6%
CyA 0.3% 0.3% 0.5% 0.7% 0.3% 0.1% 0.1% 0.1% 0.1% 0.2%
CyA + MMF/MPA 0.7% 1.0% 1.0% 2.1% 0.9% 0.8% 2.0% 1.9% 1.6% 1.9%
CyA + MMF/MPA + OtherAntimet 0.5% 0.2% 0.5% 0.1% 0.0% 0.1% 0.9% 1.1% 0.3% 0.1%
CyA + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.2% 0.0% 0.0%
CyA + MMF/MPA + Steroids 22.4% 33.1% 39.7% 53.7% 51.3% 41.9% 41.7% 38.7% 31.1% 28.5%
CyA + OtherAntimet 2.3% 1.4% 0.8% 1.2% 0.5% 0.6% 0.5% 0.8% 0.4% 0.2%
CyA + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0%
CyA + OtherAntimet + Steroids 52.6% 38.7% 24.5% 14.6% 10.0% 6.6% 4.4% 3.8% 2.2% 2.0%
CyA + Siro/Evero 0.0% 0.0% 0.0% 0.1% 0.0% 0.1% 0.1% 0.0% 0.1% 0.1%
CyA + Siro/Evero + Steroids 0.0% 0.1% 1.0% 0.9% 0.2% 0.9% 2.0% 0.3% 0.4% 2.4%
CyA + Steroids 4.2% 3.7% 10.8% 3.8% 1.5% 2.3% 1.8% 0.6% 0.7% 1.2%
Tac 0.0% 0.1% 0.1% 0.1% 0.3% 0.1% 0.4% 0.2% 0.4% 0.6%
Tac + MMF/MPA 0.0% 0.2% 0.1% 0.3% 0.4% 0.9% 2.7% 2.7% 2.7% 3.8%
Tac + MMF/MPA + OtherAntimet 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.0% 0.1%
Tac + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.1% 0.1% 0.1% 0.1% 0.2% 0.2% 0.1%
Tac + MMF/MPA + Steroids 2.6% 5.8% 8.1% 8.7% 19.3% 23.7% 27.5% 36.2% 46.0% 48.7%
Tac + OtherAntimet 0.0% 0.0% 0.2% 0.1% 0.1% 0.1% 0.1% 0.2% 0.2% 0.1%
Tac + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0%
Tac + OtherAntimet + Steroids 3.2% 2.5% 1.9% 2.1% 1.4% 1.4% 1.4% 1.0% 0.8% 1.3%
Tac + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.1% 0.2% 0.1% 0.1% 0.3% 0.4%
Tac + Siro/Evero + Steroids 0.0% 0.0% 0.1% 0.9% 2.1% 5.5% 1.9% 0.9% 0.8% 0.9%
Tac + Steroids 2.4% 1.6% 2.2% 1.9% 3.4% 3.7% 2.8% 2.1% 2.0% 1.9%
Other Regimen 5.4% 7.8% 5.0% 4.8% 6.9% 8.2% 7.9% 6.7% 7.2% 4.0%


Source: OPTN/SRTR Data as of May 1, 2007.

Percentages in each column sum to 100 percent.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.